The choice of antipsychotic drugs for schizophrenia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.The Journal of clinical psychiatry · 2013
   Trial
2. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study.Journal of child and adolescent psychopharmacology · 2008
   Trial
3. How Early-Life Antipsychotic Drug Administration Modifies Behavioral and Brain Function in Adulthood.Current topics in behavioral neurosciences · 2025
   Review
4. Attenuated Weight Gain with the Novel Analog of Olanzapine Linked to Sarcosinyl Moiety (PGW5) Compared to Olanzapine.Journal of molecular neuroscience : MN · 2016
   Article
5. Intentional rechallenge: does the benefit outweigh the risk?Drug safety · 2013
   Article
6. Passive and active schizophrenia: toward a new descriptive micropsychopathology.Schizophrenia bulletin · 2009
   Article
7. Asenapine.CNS drugs · 2009
   Review
8. Clozapine interaction with phosphatidyl inositol 3-kinase (PI3K)/insulin-signaling pathway in Caenorhabditis elegans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2009
   Article
9. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2008
   Review
10. Who are the new users of antipsychotic medications?Psychiatric services (Washington, D.C.) · 2008
    Article
11. Pancreatitis following Olanzapine Therapy: A Report of Three Cases.Case reports in gastroenterology · 2007
    Article
12. Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine.Biological psychiatry · 2007
    Article
13. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms.Journal of neural transmission (Vienna, Austria : 1996) · 2007
    Review
14. Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.Health affairs (Project Hope)
    Article

Corrections and comments

• Comment on
  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.2005

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as